Elevated TRIM47 expression correlates with advanced tumor stage, metastasis, and poor prognosis in cancer

Photo by Bioscience Image Library by Fayette Reynolds / Unsplash

Frontiers in Medicine Published June 5, 2026 Medically reviewed June 5, 2026 Study authors: Qingsong Wang, Xiaojian Zhuo, Xianmin Wang, Tongyong Luo, Jun Yin DOI ↗ By Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development

Key Takeaway

Note that elevated TRIM47 expression correlates with advanced stage, metastasis, and poor prognosis.

This narrative review evaluates the translational feasibility and distinct obstacles of TRIM47-targeted precision nanomedicine. The scope focuses on the relationship between TRIM47 expression and clinical outcomes rather than trial-level data. The authors synthesize that elevated TRIM47 expression correlates with advanced tumor stage, metastasis, and poor prognosis. No specific sample sizes or p-values are reported for these associations. The review does not provide absolute numbers or confidence intervals for these correlations. Instead, it highlights the conceptual challenges inherent in targeting this protein systemically. The authors emphasize that direct systemic therapeutic targeting of TRIM47 remains conceptually challenged by substantial on-target toxicities. These risks include lethal autoimmune inflammation and blood-brain barrier disruption. The review does not report discontinuation rates or tolerability data. Furthermore, the potential of TRIM47 as a pan-cancer predictive biomarker is not overstated. The study does not report a specific population or setting. The authors caution that the evidence is limited by these substantial on-target toxicities. This narrative review provides a qualitative assessment of the current state of TRIM47 targeting.

Study Details

Study typeSystematic review

EvidenceLevel 1

PublishedMay 2026

View Original Abstract ↓

TRIM47 is a core member of the tripartite motif (TRIM) family of E3 ubiquitin ligases, characterized by an N-terminal RBCC motif and a C-terminal PRY-SPRY domain that flexibly catalyze both K48- and K63-linked ubiquitination. Under physiological conditions, TRIM47 functions as a crucial safety valve for immunological and neurovascular homeostasis, primarily by degrading innate immune signaling hubs (such as MAVS) to prevent hematopoietic stem cell exhaustion and by stabilizing antioxidant responses in the central nervous system. However, in the tumor microenvironment (TME), TRIM47 undergoes profound functional reprogramming driven by specific post-translational modifications (PTMs) and altered substrate availability. This pathogenic shift redirects its ubiquitin ligase activity toward the targeted degradation of critical tumor suppressors and metabolic enzymes, while persistently activating pro-survival signaling cascades, such as the NF-κB and Wnt/β-catenin pathways. Consequently, TRIM47 drives malignant progression, metabolic reprogramming, and multidrug resistance across diverse anatomical systems, concurrently remodeling the TME toward an immunosuppressive state via altered metabolic byproducts. Clinically, elevated TRIM47 expression strongly correlates with advanced tumor stage, metastasis, and poor prognosis, establishing its robust potential as a pan-cancer predictive biomarker. Despite this, direct systemic therapeutic targeting of TRIM47 remains conceptually challenged by substantial on-target toxicities, including lethal autoimmune inflammation and blood-brain barrier disruption. This review systematically delineates the structural basis and context-dependent regulatory networks of TRIM47, critically evaluates its transition from a physiological guardian to a pathological driver, and assesses the translational feasibility and distinct obstacles of TRIM47-targeted precision nanomedicine.